Investigation into Novo Nordisk A/S (NVO) over securities fraud allegations persists, prompting those who incurred losses to reach out to the Law Offices of Frank R. Cruz for potential legal action.
Investors who have purchased Novo Nordisk securities are encouraged to inquire about potentially pursuing a claim to recover their losses, as an investigation is ongoing into potential violations of federal securities laws by Novo Nordisk A/S (NVO).
The investigation, led by The Law Offices of Frank R. Cruz, was prompted by the announcement on June 23, 2025, that Novo Nordisk ended its partnership with Hims & Hers Health, Inc. and that Wegovy would no longer be available through Hims. The move was due to Hims' violation of a law prohibiting mass sales of compounded drugs under the guise of 'personalization' and deceptive marketing that put patient safety at risk.
Following this announcement, Novo Nordisk's stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025. The investigation was further escalated when, on July 29, 2025, Novo Nordisk cut its previously issued guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s. As a result, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025.
The Law Offices of Frank R. Cruz, located in Century City, California at 2121 Avenue of the Stars, Suite 800, are encouraging investors who have purchased Novo Nordisk securities to inquire about potentially pursuing a claim to recover their loss. Contact information for The Law Offices of Frank R. Cruz includes mailing address, telephone number, email address, website, and Twitter handle. The website for The Law Offices of Frank R. Cruz is www.frankcruzlaw.com, and the Twitter handle is twitter.com/FRC_LAW. If inquiring by email, investors are asked to include their mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. It is important to note that past results do not guarantee future outcomes, and investors should seek legal advice from their own counsel before taking any action based on this information.
Investors who are interested in participating in the investigation or learning more about their potential legal rights and options are encouraged to contact The Law Offices of Frank R. Cruz at (310) 914-5007 or by email at [email protected]. The name of the prosecutor in the investigation against Novo Nordisk A/S is not publicly disclosed.
Read also:
- chaos unveiled on Clowning Street: week 63's antics from 'Two-Tier Keir' and his chaotic Labour Circus
- Skechers Debuts First American Stores Focused on Athletic Footwear Performance
- Budget discrepancy jeopardizes highway projects' financial support
- Racing ahead in Renewable Energy Dominance: Changzhou, Jiangsu Pushes for Worldwide Renewable Energy Ascendancy
%20over%20securities%20fraud%20allegations%20persists%2C%20prompting%20those%20who%20incurred%20losses%20to%20reach%20out%20to%20the%20Law%20Offices%20of%20Frank%20R.%20Cruz%20for%20potential%20legal%20action.){kind=link}